Antiphospholipid syndrome (APS) and myeloproliferative neoplasms (MPN) are associated with an increased risk of thrombosis. The optimal management of patients with coexistent APS and MPN has not been defined. A single centre and systematic literature review of patients with coexistent APS and MPN was performed. Cases were divided into two groups based on whether they met international consensus criteria for APS. Of the 12 studies identified, eight were excluded (leaving five of a total 54 patients), as although antiphospholipid antibodies (aPL) were documented, the diagnosis of APS was not conclusively demonstrated. Another ten patients with definite APS were identified at our centre. Fifteen patients (ten females, five males) were therefore included in this analysis (eleven definite APS and four highly likely), median age 44 (range: 13–71) years. Nine had polycythaemia vera and six, essential thrombocythaemia. Thirteen of the 15 patients (86.7%) had thrombotic APS (seven with initial venous events and six arterial) and two (13.3%) had obstetric APS. Nine patients were single-positive, and six double-positive for aPL. None were triple aPL-positive. Four patients at our centre had recurrent thrombotic/obstetric events, including while on anticoagulation/antiplatelet treatment.
MiyakisSLockshinMDAtsumiT, et al.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006;
4: 295–306.
ZuilySCohenHIsenbergD, et al.
Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: guidance from the scientific and standardization committee of the international society on thrombosis and haemostasis. J Thromb Haemost2020;
18: 2126–2137.
4.
Cohen H, Cuadrado MJ, Erkan D, et al. 16th international congress of antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. Lupus 2020; 1571--1593.
5.
HolbrookASchulmanSWittDM, et al.
Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis: American college of chest physicians evidence-based clinical practice guidelines. Chest2012;
141: e152–S84.
6.
KeelingDMackieIMooreGWGreerIAGreavesM; British Committee for Standards in Haematology.
Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol2012;
157: 47–58.
7.
TektonidouMGAndreoliLLimperM, et al.
EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis2019;
78: 1296–1304.
8.
CrowtherMAGinsbergJSJulianJ, et al.
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med2003;
349: 1133–1138.
9.
FinazziGMarchioliRBrancaccioV, et al.
A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome. J Thromb Haemost2005;
3: 848–853.
10.
CerveraRKhamashtaMAShoenfeldY, et al.; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies).
Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis2009;
68: 1428–1432.
11.
PengoVRuffattiALegnaniC, et al.
Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome. Journal of Thrombosis and Haemostasis2010;
8: 237–242.
12.
VannucchiAMHarrisonCN.Emerging treatments for classical myeloproliferative neoplasms. Blood2017;
129: 693–703.
13.
CasiniAFontanaPLecompteTP.Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk‐guided management. J Thromb Haemost2013;
11: 1215–1227.
14.
CervantesFPassamontiFBarosiG.Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia2008;
22: 905–914.
15.
RandiMLBertozziIRumiE, et al.
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. Am J Hematol2014;
89: 306–309.
16.
Ammon AvalosLGalindoCLiD.A systematic review to calculate background miscarriage rates using life table analysis. Birth Defects Res Part A: Clin Mol Teratol2012;
94: 417–423.
17.
BarbuiTFinazziGFalangaA.Myeloproliferative neoplasms and thrombosis. Blood2013;
122: 2176–2184.
18.
BarbuiTBarosiGBirgegardG, et al.; European LeukemiaNet.
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol2011;
29: 761–770.
19.
CortelazzoSFinazziGRuggeriM, et al.
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med1995;
332: 1132–1137.
20.
HarrisonCNCampbellPJBuckG, et al.
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med2005;
353: 33–45.
21.
ElliottMATefferiA.Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol2005;
128: 275–290.
22.
WilleKSadjadianPBeckerT, et al.
High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. Ann Hematol2019;
98: 93–100.
23.
De StefanoVZaTRossiE, et al.; for the GIMEMA CMD-Working Party.
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica2008;
93: 372–380.
24.
MuradSDPlessierAHernandez-GuerraM, et al.; EN-Vie (European Network for Vascular Disorders of the Liver).
Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med2009;
151: 167–175.
25.
HarrisonCDonohoeSCarrPDaveMMackieIMachinS.Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thromb Haemost2002;
87: 802–807.
26.
JensenMKde Nully BrownPThorsenSHasselbalchHC.Frequent occurrence of anticardiolipin antibodies, factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders. Am J Hematol2002;
69: 185–191.
27.
Royal College of Physicians Intercollegiate Stroke Working Party 2016. National Clinical Guideline for Stroke. https://www.rcplondon.ac.uk/guidelines-policy/stroke-guidelines
28.
Barcellini W, Giannotta JA, Fattizzo B. Autoimmune complications in hematologic neoplasms. Cancers 2021; 26: 13.
29.
KristinssonSYLandgrenOSamuelssonJBjorkholmMGoldinLR.Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica2010;
95: 1216–1220.
30.
HarrisonCNMachinSJ.Antiphospholipid antibodies and essential thrombocythemia. Am J Med1997;
102: 317–318.
De GrootPUrbanusRDerksenR.Pathophysiology of thrombotic APS: where do we stand?Lupus2012;
21: 704–707.
33.
GarciaDErkanD.Diagnosis and management of the antiphospholipid syndrome. N Engl J Med2018;
378: 2010–2021.
34.
YalavarthiSGouldTJRaoAN, et al.
Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol2015;
67: 2990–3003.
35.
ZuoYYalavarthiSGockmanK, et al.
Anti-neutrophil extracellular trap antibodies and impaired neutrophil extracellular trap degradation in antiphospholipid syndrome. Arthritis Rheumatol2020;
72: 2130–2135.
36.
WolachOSellarRSMartinodK, et al.
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med2018;
11: 436.
PengoVRuffattiALegnaniC, et al.
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood2011;
118: 4714–4718.
39.
RosoveMHBrewerPM.Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med1992;
117: 303–308.
40.
KhamashtaMACuadradoMJMujicFTaubNAHuntBJHughesGR.The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med1995;
332: 993–997.
41.
De StefanoVCarobbioADi LazzaroV, et al.
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. Blood Cancer J2018;
8: 1–12.
42.
Sanchez-RedondoJEspinosaGDelgadoDVCerveraR.Recurrent thrombosis with direct oral anticoagulants in antiphospholipid syndrome: a systematic literature review and Meta-analysis. Clin Ther2019;
41: 1839–1862.
43.
DufrostVRisseJZuilySWahlD.Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature. Curr Rheumatol Rep2016;
18: 74.
